2018年Otto Aufranc奖:全基因组变异如何影响全髋关节置换术后骨溶解风险
研究基于挪威队列2624例和英国队列890例全髋关节置换术后患者,开展两项全基因组关联研究,分别分析与骨溶解易感性及因骨溶解行翻修手术时间相关的遗传位点。荟萃分析发现5个独立遗传信号与骨溶解病例对照状态 suggestive 相关,11个独立遗传信号与翻修时间 suggestive 相关。作者认为需进一步研究确定因果关系及功能作用。
要点
- 全基因组关联分析在挪威队列发现4个、英国队列发现11个与骨溶解易感性 suggestive 相关的独立遗传信号。
- 荟萃分析后5个独立遗传信号与骨溶解病例对照状态 suggestive 相关,最强信号位于7号染色体(lead signal rs850092,p=1.13×10)。
- 荟萃分析后11个独立遗传信号与翻修时间 suggestive 相关,最大关联块位于15号染色体(lead signal rs10507055,p=1.40×10)。
核心结论
- 在全基因组水平探索了骨溶解的遗传生物学,识别出多个与骨溶解易感性或早期翻修手术相关的遗传位点。
- 作者认为需要进一步研究来确定所识别信号与骨溶解之间的因果关系及其在疾病中的功能作用。
研究设计与样本
- 研究纳入挪威关节置换登记处招募的2624例全髋关节置换术后患者(其中779例因骨溶解接受翻修手术)和英国北部医院招募的890例患者(其中317例有骨溶解影像学证据和/或因骨溶解接受翻修手术)。
- 所有参与者均接受全骨水泥或混合型全髋关节置换,使用小直径金属或陶瓷对传统聚乙烯负重面。
- 在每个队列分别进行全基因组基因分型后,开展骨溶解易感性病例对照分析和翻修时间(骨溶解发生速度的替代指标)的数量性状分析,最后对两个独立队列的关联分析结果进行荟萃分析。
主要发现
- 全基因组关联分析在挪威队列发现4个、英国队列发现11个与骨溶解病例对照状态 suggestive 相关的独立遗传信号(p≤5×10)。
- 荟萃分析后,5个独立遗传信号在p≤5×10水平与骨溶解病例对照状态显示 suggestive 关联,最强信号包括7号染色体上18个相关变异(lead signal rs850092,p=1.13×10)。
- 仅在病例中进行的全基因组数量性状分析显示,挪威队列和英国队列分别有5个和9个独立遗传信号与翻修时间 suggestive 相关(p≤5×10)。
- 荟萃分析后,11个独立遗传信号在p≤5×10水平与翻修时间显示 suggestive 关联证据,最大关联块包括15号染色体上174个相关变异(lead signal rs10507055,p=1.40×10)。
临床怎么用
- 作者指出,识别骨溶解的新遗传风险位点为该疾病的临床生物标志物发现和治疗干预提供了新的研究途径。
- 作者认为需要进一步研究来确定所识别信号与骨溶解之间的因果关系及其功能作用。
局限性
- 作者指出需要进一步研究来确定所识别信号与骨溶解之间的因果关系及其在疾病中的功能作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic osteolysis resulting in aseptic loosening is a leading cause of THA revision. Individuals vary in their susceptibility to osteolysis and heritable factors may contribute to this variation. However, the overall contribution that such variation makes to osteolysis risk is unknown. QUESTIONS/PURPOSES: We conducted two genome-wide association studies to (1) identify genetic risk loci associated with susceptibility to osteolysis; and (2) identify genetic risk loci associated with time to prosthesis revision for osteolysis. METHODS: The Norway cohort comprised 2624 patients after THA recruited from the Norwegian Arthroplasty Registry, of whom 779 had undergone revision surgery for osteolysis. The UK cohort included 890 patients previously recruited from hospitals in the north of England, 317 who either had radiographic evidence of and/or had undergone revision surgery for osteolysis. All participants had received a fully cemented or hybrid THA using a small-diameter metal or ceramic-on-conventional polyethylene bearing. Osteolysis susceptibility case-control analyses and quantitative trait analyses for time to prosthesis revision (a proxy measure of the speed of osteolysis onset) in those patients with osteolysis were undertaken in each cohort separately after genome-wide genotyping. Finally, a meta-analysis of the two independent cohort association analysis results was undertaken. RESULTS: Genome-wide association analysis identified four independent suggestive genetic signals for osteolysis case-control status in the Norwegian cohort and 11 in the UK cohort (p ≤ 5 x 10). After meta-analysis, five independent genetic signals showed a suggestive association with osteolysis case-control status at p ≤ 5 x 10 with the strongest comprising 18 correlated variants on chromosome 7 (lead signal rs850092, p = 1.13 x 10). Genome-wide quantitative trait analysis in cases only showed a total of five and nine independent genetic signals for time to revision at p ≤ 5 x 10, respectively. After meta-analysis, 11 independent genetic signals showed suggestive evidence of an association with time to revision at p ≤ 5 x 10 with the largest association block comprising 174 correlated variants in chromosome 15 (lead signal rs10507055, p = 1.40 x 10). CONCLUSIONS: We explored the heritable biology of osteolysis at the whole genome level and identify several genetic loci that associate with susceptibility to osteolysis or with premature revision surgery. However, further studies are required to determine a causal association between the identified signals and osteolysis and their functional role in the disease. CLINICAL RELEVANCE: The identification of novel genetic risk loci for osteolysis enables new investigative avenues for clinical biomarker discovery and therapeutic intervention in this disease.
引用
- MacInnes SJ, Hatzikotoulas K, Fenstad AM, et al. The 2018 Otto Aufranc Award: How Does Genome-wide Variation Affect Osteolysis Risk After THA? Clin Orthop Relat Res. 2019. PMID: 30794219. doi:10.1097/01.blo.0000533629.49193.09
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。